Comorbidity Assessment in Localized Prostate Cancer: A Review of Currently Available Techniques
Pathological nomograms have allowed urologists to make accurate predictions about the behaviour of localized prostate cancers. However, predicting overall outcome and survival is not solely dependent on tumour characteristics; comorbidity is also a vital determinant of outcome The majority of prosta...
Gespeichert in:
| Veröffentlicht in: | European Urology 2004-07, Vol.46 (1), p.28-41 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 41 |
|---|---|
| container_issue | 1 |
| container_start_page | 28 |
| container_title | European Urology |
| container_volume | 46 |
| creator | Singh, Rajinder O’Brien, T.S |
| description | Pathological nomograms have allowed urologists to make accurate predictions about the behaviour of localized prostate cancers. However, predicting overall outcome and survival is not solely dependent on tumour characteristics; comorbidity is also a vital determinant of outcome The majority of prostate cancers are diagnosed in men over 65 years of age and many will have significant competing comorbid disease that will need to be accounted when considering eligibility for radical treatment.
Most urologists currently make an educated guess about the risk posed by comorbid disease. Such an approach has the potential to allow personal bias to influence what should be an objective measure. This review describes the available methods for objectively assessing comorbid risk and assesses their potential utility to men with localized prostate cancer being considered for radical treatment. |
| doi_str_mv | 10.1016/j.eururo.2004.01.010 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72005194</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0302283804000132</els_id><sourcerecordid>72005194</sourcerecordid><originalsourceid>FETCH-LOGICAL-c358t-22d2af192a693b23e9d924b3dc70c1f7338fab2cac71075a43da9f24870a56233</originalsourceid><addsrcrecordid>eNp9kF1r2zAUhsXoWNJ0_6AUXe3O3pFkxXYvCsF06yCwMdJrIUvHVMG2WsluSX_9FBLYXeGFc_N-cB5CrhnkDNj6-z7HOczB5xygyIElwSeyZFUpslKu4YIsQQDPeCWqBbmMcQ8AQtbiC1kwySohC7kkqvGDD62zbjrQTYwY44DjRN1It97o3r2jpX-Cj5OekDZ6NBhu6Yb-xVeHb9R3tJlDSIk-xV-163XbI92heRrdy4zxinzudB_x6_muyOOP-13zkG1___zVbLaZEbKaMs4t1x2ruV7XouUCa1vzohXWlGBYVwpRdbrlRpuSQSl1IayuO15UJWi55kKsyLdT73Pwx91JDS4a7Hs9op-jKhMlyeoiGYuT0aSnYsBOPQc36HBQDNQRrNqrE1h1BKuAJUGK3Zz753ZA-z90JpkMdycDpi8Tm6CicZhwWRfQTMp69_HCP07yjBc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72005194</pqid></control><display><type>article</type><title>Comorbidity Assessment in Localized Prostate Cancer: A Review of Currently Available Techniques</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Singh, Rajinder ; O’Brien, T.S</creator><creatorcontrib>Singh, Rajinder ; O’Brien, T.S</creatorcontrib><description>Pathological nomograms have allowed urologists to make accurate predictions about the behaviour of localized prostate cancers. However, predicting overall outcome and survival is not solely dependent on tumour characteristics; comorbidity is also a vital determinant of outcome The majority of prostate cancers are diagnosed in men over 65 years of age and many will have significant competing comorbid disease that will need to be accounted when considering eligibility for radical treatment.
Most urologists currently make an educated guess about the risk posed by comorbid disease. Such an approach has the potential to allow personal bias to influence what should be an objective measure. This review describes the available methods for objectively assessing comorbid risk and assesses their potential utility to men with localized prostate cancer being considered for radical treatment.</description><identifier>ISSN: 0302-2838</identifier><identifier>EISSN: 1873-7560</identifier><identifier>DOI: 10.1016/j.eururo.2004.01.010</identifier><identifier>PMID: 15183545</identifier><language>eng</language><publisher>Switzerland: Elsevier B.V</publisher><subject>Cardiovascular Diseases - complications ; Cardiovascular Diseases - epidemiology ; Comorbidity ; Comorbidity assessment ; Humans ; Localized prostate cancer ; Male ; Prostatic Neoplasms - complications ; Prostatic Neoplasms - epidemiology ; Risk Assessment ; Validated techniques</subject><ispartof>European Urology, 2004-07, Vol.46 (1), p.28-41</ispartof><rights>2004</rights><rights>Copyright 2004 Elsevier B.V.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c358t-22d2af192a693b23e9d924b3dc70c1f7338fab2cac71075a43da9f24870a56233</citedby><cites>FETCH-LOGICAL-c358t-22d2af192a693b23e9d924b3dc70c1f7338fab2cac71075a43da9f24870a56233</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0302283804000132$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>313,314,776,780,788,3537,27899,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15183545$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Singh, Rajinder</creatorcontrib><creatorcontrib>O’Brien, T.S</creatorcontrib><title>Comorbidity Assessment in Localized Prostate Cancer: A Review of Currently Available Techniques</title><title>European Urology</title><addtitle>Eur Urol</addtitle><description>Pathological nomograms have allowed urologists to make accurate predictions about the behaviour of localized prostate cancers. However, predicting overall outcome and survival is not solely dependent on tumour characteristics; comorbidity is also a vital determinant of outcome The majority of prostate cancers are diagnosed in men over 65 years of age and many will have significant competing comorbid disease that will need to be accounted when considering eligibility for radical treatment.
Most urologists currently make an educated guess about the risk posed by comorbid disease. Such an approach has the potential to allow personal bias to influence what should be an objective measure. This review describes the available methods for objectively assessing comorbid risk and assesses their potential utility to men with localized prostate cancer being considered for radical treatment.</description><subject>Cardiovascular Diseases - complications</subject><subject>Cardiovascular Diseases - epidemiology</subject><subject>Comorbidity</subject><subject>Comorbidity assessment</subject><subject>Humans</subject><subject>Localized prostate cancer</subject><subject>Male</subject><subject>Prostatic Neoplasms - complications</subject><subject>Prostatic Neoplasms - epidemiology</subject><subject>Risk Assessment</subject><subject>Validated techniques</subject><issn>0302-2838</issn><issn>1873-7560</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kF1r2zAUhsXoWNJ0_6AUXe3O3pFkxXYvCsF06yCwMdJrIUvHVMG2WsluSX_9FBLYXeGFc_N-cB5CrhnkDNj6-z7HOczB5xygyIElwSeyZFUpslKu4YIsQQDPeCWqBbmMcQ8AQtbiC1kwySohC7kkqvGDD62zbjrQTYwY44DjRN1It97o3r2jpX-Cj5OekDZ6NBhu6Yb-xVeHb9R3tJlDSIk-xV-163XbI92heRrdy4zxinzudB_x6_muyOOP-13zkG1___zVbLaZEbKaMs4t1x2ruV7XouUCa1vzohXWlGBYVwpRdbrlRpuSQSl1IayuO15UJWi55kKsyLdT73Pwx91JDS4a7Hs9op-jKhMlyeoiGYuT0aSnYsBOPQc36HBQDNQRrNqrE1h1BKuAJUGK3Zz753ZA-z90JpkMdycDpi8Tm6CicZhwWRfQTMp69_HCP07yjBc</recordid><startdate>20040701</startdate><enddate>20040701</enddate><creator>Singh, Rajinder</creator><creator>O’Brien, T.S</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20040701</creationdate><title>Comorbidity Assessment in Localized Prostate Cancer: A Review of Currently Available Techniques</title><author>Singh, Rajinder ; O’Brien, T.S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c358t-22d2af192a693b23e9d924b3dc70c1f7338fab2cac71075a43da9f24870a56233</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Cardiovascular Diseases - complications</topic><topic>Cardiovascular Diseases - epidemiology</topic><topic>Comorbidity</topic><topic>Comorbidity assessment</topic><topic>Humans</topic><topic>Localized prostate cancer</topic><topic>Male</topic><topic>Prostatic Neoplasms - complications</topic><topic>Prostatic Neoplasms - epidemiology</topic><topic>Risk Assessment</topic><topic>Validated techniques</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Singh, Rajinder</creatorcontrib><creatorcontrib>O’Brien, T.S</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European Urology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Singh, Rajinder</au><au>O’Brien, T.S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comorbidity Assessment in Localized Prostate Cancer: A Review of Currently Available Techniques</atitle><jtitle>European Urology</jtitle><addtitle>Eur Urol</addtitle><date>2004-07-01</date><risdate>2004</risdate><volume>46</volume><issue>1</issue><spage>28</spage><epage>41</epage><pages>28-41</pages><issn>0302-2838</issn><eissn>1873-7560</eissn><abstract>Pathological nomograms have allowed urologists to make accurate predictions about the behaviour of localized prostate cancers. However, predicting overall outcome and survival is not solely dependent on tumour characteristics; comorbidity is also a vital determinant of outcome The majority of prostate cancers are diagnosed in men over 65 years of age and many will have significant competing comorbid disease that will need to be accounted when considering eligibility for radical treatment.
Most urologists currently make an educated guess about the risk posed by comorbid disease. Such an approach has the potential to allow personal bias to influence what should be an objective measure. This review describes the available methods for objectively assessing comorbid risk and assesses their potential utility to men with localized prostate cancer being considered for radical treatment.</abstract><cop>Switzerland</cop><pub>Elsevier B.V</pub><pmid>15183545</pmid><doi>10.1016/j.eururo.2004.01.010</doi><tpages>14</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0302-2838 |
| ispartof | European Urology, 2004-07, Vol.46 (1), p.28-41 |
| issn | 0302-2838 1873-7560 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_72005194 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Cardiovascular Diseases - complications Cardiovascular Diseases - epidemiology Comorbidity Comorbidity assessment Humans Localized prostate cancer Male Prostatic Neoplasms - complications Prostatic Neoplasms - epidemiology Risk Assessment Validated techniques |
| title | Comorbidity Assessment in Localized Prostate Cancer: A Review of Currently Available Techniques |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T02%3A08%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comorbidity%20Assessment%20in%20Localized%20Prostate%20Cancer:%20A%20Review%20of%20Currently%20Available%20Techniques&rft.jtitle=European%20Urology&rft.au=Singh,%20Rajinder&rft.date=2004-07-01&rft.volume=46&rft.issue=1&rft.spage=28&rft.epage=41&rft.pages=28-41&rft.issn=0302-2838&rft.eissn=1873-7560&rft_id=info:doi/10.1016/j.eururo.2004.01.010&rft_dat=%3Cproquest_cross%3E72005194%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=72005194&rft_id=info:pmid/15183545&rft_els_id=S0302283804000132&rfr_iscdi=true |